{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:28:16Z","timestamp":1777577296225,"version":"3.51.4"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005302","name":"Alexander S. Onassis Public Benefit Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of functional dystrophin protein. Patients experience progressive muscle weakness, cardiomyopathy and have a decreased life expectancy. Standards of care, including treatment with steroids, and multidisciplinary approaches have extended the life expectancy and improved the quality of life of patients. In the last 30\u00a0years, several compounds have been assessed in preclinical and clinical studies for their ability to restore functional dystrophin levels or to modify pathways involved in DMD pathophysiology. However, there is still an unmet need with regards to a disease-modifying treatment for DMD and the attrition rate between early-phase and late-phase clinical development remains high. Currently, there are 40 compounds in clinical development for DMD, including gene therapy and antisense oligonucleotides for exon skipping. Only five of them have received conditional approval in one jurisdiction subject to further proof of efficacy. In this review, we present data of another 16 compounds that failed to complete clinical development, despite positive results in early phases of development in some cases. We examine the reasons for the high attrition rate and we suggest solutions to avoid similar mistakes in the future.<\/jats:p>","DOI":"10.3389\/fphar.2021.735912","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T07:04:22Z","timestamp":1635750262000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy"],"prefix":"10.3389","volume":"12","author":[{"given":"Theodora","family":"Markati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urlike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why Dystrophin Quantification Is Key in the Eteplirsen Saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JND-180357","article-title":"Report of a TREAT-NMD\/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology","volume":"6","author":"Aartsma-Rus","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic Delivery of Morpholino Oligonucleotide Restores Dystrophin Expression Bodywide and Improves Dystrophic Pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0141240","DOI":"10.1371\/journal.pone.0141240","article-title":"Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy, Editor A. Kumar","volume":"10","author":"Barp","year":"2015","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13395-020-00239-0","article-title":"X-linked Muscular Dystrophy in a Labrador Retriever Strain: Phenotypic and Molecular Characterisation","volume":"10","author":"Barth\u00e9l\u00e9my","year":"2020","journal-title":"Skelet Muscle"},{"key":"B8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/acn3.51046","article-title":"Genetic Modifiers of Respiratory Function in Duchenne Muscular Dystrophy","volume":"7","author":"Bello","year":"2020","journal-title":"Ann. Clin. Transl Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","article-title":"DMD Genotypes and Loss of Ambulation in the CINRG Duchenne Natural History Study","volume":"87","author":"Bello","year":"2016","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and Management of Duchenne Muscular Dystrophy, Part 2: Respiratory, Cardiac, Bone Health, and Orthopaedic Management","volume":"17","author":"Birnkrant","year":"","journal-title":"Lancet Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Neuromuscular, Rehabilitation, Endocrine, and Gastrointestinal and Nutritional Management","volume":"17","author":"Birnkrant","year":"","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and Management of Duchenne Muscular Dystrophy, Part 3: Primary Care, Emergency Management, Psychosocial Care, and Transitions of Care across the Lifespan","volume":"17","author":"Birnkrant","year":"","journal-title":"Lancet Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/ppul.22688","article-title":"Effects of Glucocorticoids and Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy","volume":"48","author":"Buyse","year":"2013","journal-title":"Pediatr. Pulmonol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/eurheartj\/ehn406","article-title":"Long-term Blinded Placebo-Controlled Study of SNT-MC17\/idebenone in the Dystrophin Deficient Mdx Mouse: Cardiac protection and Improved Exercise Performance","volume":"30","author":"Buyse","year":"2009","journal-title":"Eur. Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ppul.23547","article-title":"Treatment Effect of Idebenone on Inspiratory Function in Patients with Duchenne Muscular Dystrophy","volume":"52","author":"Buyse","year":"2017","journal-title":"Pediatr. Pulmonol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of Idebenone on Respiratory Function in Patients with Duchenne Muscular Dystrophy Not Using Glucocorticoids (DELOS): a Double-Blind Randomised Placebo-Controlled Phase 3 Trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin Inhibitor ACE-031 Treatment of Ambulatory Boys with Duchenne Muscular Dystrophy: Results of a Randomized, Placebo-Controlled Clinical Trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"B18","first-page":"5","article-title":"Age at Onset of First Signs or Symptoms Predicts Age at Loss of Ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet","volume-title":"Age at Onset of First Signs or Symptoms Predicts Age at Loss of Ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet","author":"Ciafaloni","year":"2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","article-title":"Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy","volume":"89","author":"de Feraudy","year":"2021","journal-title":"Ann. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.rh.2016.09.006","article-title":"Influencia de los esteroides en los parametros de la marcha en distrofia de Duchenne","volume":"51","author":"de la Pe\u00f1a","year":"2017","journal-title":"Rehabilitaci\u00f3n"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.nmd.2020.05.001","article-title":"Combining Genetics, Neuropsychology and Neuroimaging to Improve Understanding of Brain Involvement in Duchenne Muscular Dystrophy - a Narrative Review","volume":"30","author":"Doorenweerd","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.jval.2021.04.1023","article-title":"PRO38 Twenty Years of Clinical Trials in Duchenne Muscular Dystrophy: A Low Clinical Drug Development Success","volume":"24","author":"Dovari","year":"2021","journal-title":"Value in Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne Muscular Dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B25","article-title":"Duchenne Muscular Dystrophy Animal Models","volume-title":"Animal Models in Medicine and Biology","author":"Egorova","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JND-180341","article-title":"Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-\u039ab Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy","volume":"6","author":"Finanger","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nmd.2021.02.001","article-title":"Disease-modifying Effects of Edasalonexent, an NF-\u039ab Inhibitor, in Young Boys with Duchenne Muscular Dystrophy: Results of the MoveDMD Phase 2 and Open Label Extension Trial","volume":"31","author":"Finkel","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JND-210689","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial","volume":"8","author":"Finkel","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13023-020-01663-7","article-title":"Hierarchical Bayesian Modelling of Disease Progression to Inform Clinical Trial Design in Centronuclear Myopathy","volume":"16","author":"Fouarge","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e84120","DOI":"10.1371\/journal.pone.0084120","article-title":"Six-minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to 12 Years","volume":"8","author":"Goemans","year":"2013","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A Randomized Placebo-Controlled Phase 3 Trial of an Antisense Oligonucleotide, Drisapersen, in Duchenne Muscular Dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","article-title":"Suitability of External Controls for Drug Evaluation in Duchenne Muscular Dystrophy","volume":"95","author":"Goemans","year":"2020","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0232870","DOI":"10.1371\/journal.pone.0232870","article-title":"Prognostic Factors for Changes in the Timed 4-stair Climb in Patients with Duchenne Muscular Dystrophy, and Implications for Measuring Drug Efficacy: A Multi-Institutional Collaboration","volume":"15","author":"Goemans","year":"2020","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0161955","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study","volume":"11","author":"Goemans","year":"2016","journal-title":"PLoS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.nmd.2019.06.003","article-title":"European Regulator's Views on a Wearable-Derived Performance Measurement of Ambulation for Duchenne Muscular Dystrophy Regulatory Trials","volume":"29","author":"Haberkamp","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mus.25953","article-title":"Genetic Modifiers of Duchenne and Facioscapulohumeral Muscular Dystrophies","volume":"57","author":"Hightower","year":"2018","journal-title":"Muscle Nerve"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1007\/s00415-020-09800-9","article-title":"Normalized Grip Strength Is a Sensitive Outcome Measure through All Stages of Duchenne Muscular Dystrophy","volume":"267","author":"Hogrel","year":"2020","journal-title":"J. Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/WNL.0000000000002464","article-title":"Longitudinal Functional and NMR Assessment of Upper Limbs in Duchenne Muscular Dystrophy","volume":"86","author":"Hogrel","year":"2016","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.omtm.2020.04.022","article-title":"Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients","volume":"17","author":"Koch","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e110371","DOI":"10.1371\/journal.pone.0110371","article-title":"Characterization of Dystrophin Deficient Rats: a New Model for Duchenne Muscular Dystrophy","volume":"9","author":"Larcher","year":"2014","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term Microdystrophin Gene Therapy Is Effective in a Canine Model of Duchenne Muscular Dystrophy","volume":"8","author":"Le Guiner","year":"2017","journal-title":"Nat. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil Does Not Improve Cardiomyopathy in Duchenne\/Becker Muscular Dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"59668","DOI":"10.3791\/59668","article-title":"Home-based Monitor for Gait and Activity Analysis","author":"Lilien","year":"2019","journal-title":"J. Vis. Exp."},{"key":"B44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic Delivery of Antisense Oligoribonucleotide Restores Dystrophin Expression in Body-wide Skeletal Muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of Myostatin Pathway in Neuromuscular Diseases May Explain Challenges of Anti-myostatin Therapeutic Approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3233\/JND-170245","article-title":"Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy","volume":"4","author":"Mayer","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0151445","DOI":"10.1371\/journal.pone.0151445","article-title":"Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study","volume":"11","author":"Mazzone","year":"2016","journal-title":"PLoS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a Multicentric Setting","volume":"19","author":"Mazzone","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","article-title":"Antisense Oligonucleotide-Induced Exon Skipping Restores Dystrophin Expression In Vitro in a Canine Model of DMD","volume":"13","author":"McClorey","year":"2006","journal-title":"Gene Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1242\/jcs.02482","article-title":"Improved Muscle Healing through Enhanced Regeneration and Reduced Fibrosis in Myostatin-Null Mice","volume":"118","author":"McCroskery","year":"2005","journal-title":"J. Cel Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term Effects of Glucocorticoids on Function, Quality of Life, and Survival in Patients with Duchenne Muscular Dystrophy: a Prospective Cohort Study","volume":"391","author":"McDonald","year":"","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute Walk Test and Other Endpoints in Duchenne Muscular Dystrophy: Longitudinal Natural History Observations over 48 Weeks from a Multicenter Study","volume":"48","author":"Mcdonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"B53","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/acn3.579","article-title":"Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy","volume":"5","author":"McDonald","year":"","journal-title":"Ann. Clin. Transl Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and Effectiveness of Ataluren: Comparison of Results from the STRIDE Registry and CINRG DMD Natural History Study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing Natural History Trajectories of Ambulatory Function Measured by the 6-minute Walk Distance in Patients with Duchenne Muscular Dystrophy","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising Trajectories and Individual Item Changes of the North Star Ambulatory Assessment in Patients with Duchenne Muscular Dystrophy","volume":"14","author":"Muntoni","year":"","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet","volume":"8","author":"Muntoni","year":"","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/j.nmd.2017.06.443","article-title":"PhaseOut DMD: a Phase 2, Proof of Concept, Clinical Study of Utrophin Modulation with Ezutromid","volume":"27","author":"Muntoni","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/srep05635","article-title":"Generation of Muscular Dystrophy Model Rats with a CRISPR\/Cas System","volume":"4","author":"Nakamura","year":"2015","journal-title":"Sci. Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1096\/fj.201700249R","article-title":"Phosphodiesterase 4 Inhibitor and Phosphodiesterase 5 Inhibitor Combination Therapy Has Antifibrotic and Anti-inflammatory Effects in Mdx Mice with Duchenne Muscular Dystrophy","volume":"31","author":"Nio","year":"2017","journal-title":"FASEB J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1007\/s00259-020-04988-4","article-title":"Pulmonary Function in Non-ambulatory Patients with Nonesense Mutation Duchenne Muscular Dystrophy: Stride Registry and Cinrg Dnhs Matched Cohort Analysis","volume":"62","author":"Osorio","year":"2020","journal-title":"Muscle and Nerve"},{"key":"B62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1740774517751118","article-title":"Barriers and Facilitators to Clinical Trial Participation Among Parents of Children with Pediatric Neuromuscular Disorders","volume":"15","author":"Peay","year":"2018","journal-title":"Clin. Trials"},{"key":"B63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/path.4054","article-title":"Sildenafil Reduces Respiratory Muscle Weakness and Fibrosis in the Mdx Mouse Model of Duchenne Muscular Dystrophy","volume":"228","author":"Percival","year":"2012","journal-title":"J. Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13023-021-01956-5","article-title":"Normative Data on Spontaneous Stride Velocity, Stride Length, and Walking Activity in a Non-controlled Environment","volume":"16","author":"Poleur","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"893","DOI":"10.4103\/0028-3886.232304","article-title":"Change in the Natural Profile of Duchenne Muscular Dystrophy with the Judicious Use of Steroids","volume":"66","author":"Pradhan","year":"2018","journal-title":"Neurol. India"},{"key":"B66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp-2014-309405","article-title":"The NorthStar Ambulatory Assessment in Duchenne Muscular Dystrophy: Considerations for the Design of Clinical Trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1212\/WNL.0000000000009244","article-title":"Modeling Disease Trajectory in Duchenne Muscular Dystrophy","volume":"94","author":"Rooney","year":"2014","journal-title":"Neurology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1212\/WNL.0000000000008811","article-title":"Muscle MRI: A Biomarker of Disease Severity in Duchenne Muscular Dystrophy? A Systematic Review","volume":"94","author":"Ropars","year":"2020","journal-title":"Neurology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: First Global Approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"B70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cells9122657","article-title":"The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle","volume":"9","author":"Rybalka","year":"2020","journal-title":"Cells"},{"key":"B71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dmcn.12341","article-title":"The Natural History of Duchenne Muscular Dystrophy with Corticosteroids Using the Motor Function Measure","volume":"58","author":"Schreiber","year":"2016","journal-title":"Develop. Med. Child Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0113999","DOI":"10.1371\/journal.pone.0113999","article-title":"Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-ambulant Patients with Duchenne Muscular Dystrophy: an Observational Multicenter Trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS One"},{"key":"B73","volume-title":"Long-term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-In-Human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","author":"Servais","year":""},{"key":"B74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2019.10.008","article-title":"Long-term Data with Idebenone on Respiratory Function Outcomes in Patients with Duchenne Muscular Dystrophy","volume":"30","author":"Servais","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"B75","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"B76","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/nan.12735","article-title":"Utrophin Modulator Drugs as Potential Therapies for Duchenne and Becker Muscular Dystrophies","volume":"47","author":"Soblechero\u2010Mart\u00edn","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1007\/s00018-021-03821-x","article-title":"Therapeutic Aspects of Cell Signaling and Communication in Duchenne Muscular Dystrophy","volume":"78","author":"Starosta","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/genes11080837","article-title":"Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update","volume":"11","author":"Sun","year":"2020","journal-title":"Genes (Basel)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.ejpn.2017.04.1207","article-title":"Overcoming Pharmacokinetic Challenges to Drug Administration in Duchenne Muscular Dystrophy: Lessons from Phase 1 Development of Ezutromid","volume":"21","author":"Tejura","year":"2017","journal-title":"Eur. J. Paediatric Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-017-0652-y","article-title":"Therapeutic Strategies to Address Neuronal Nitric Oxide Synthase Deficiency and the Loss of Nitric Oxide Bioavailability in Duchenne Muscular Dystrophy","volume":"12","author":"Timpani","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/antiox9121268","article-title":"Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?","volume":"9","author":"Timpani","year":"2020","journal-title":"Antioxidants"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","article-title":"Expression of Full-Length Utrophin Prevents Muscular Dystrophy in Mdx Mice","volume":"4","author":"Tinsley","year":"1998","journal-title":"Nat. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","article-title":"Antisense-induced Exon Skipping Restores Dystrophin Expression in DMD Patient Derived Muscle Cells","volume":"10","author":"van Deutekom","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"A Phase 3 Randomized Placebo-Controlled Trial of Tadalafil for Duchenne Muscular Dystrophy","volume":"89","author":"Victor","year":"2017","journal-title":"Neurology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and Efficacy of Drisapersen for the Treatment of Duchenne Muscular Dystrophy (DEMAND II): an Exploratory, Randomised, Placebo-Controlled Phase 2 Study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","article-title":"Randomized Phase 2 Trial and Open-Label Extension of Domagrozumab in Duchenne Muscular Dystrophy","volume":"30","author":"Wagner","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1073\/pnas.0408729102","article-title":"Muscle Regeneration in the Prolonged Absence of Myostatin","volume":"102","author":"Wagner","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B88","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/ana.10385","article-title":"Loss of Myostatin Attenuates Severity of Muscular Dystrophy in Mdx Mice","volume":"52","author":"Wagner","year":"2002","journal-title":"Ann. Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","article-title":"The Elusive Promise of Myostatin Inhibition for Muscular Dystrophy","volume":"33","author":"Wagner","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"B90","first-page":"P1.6","article-title":"A Phase 1b\/2 Study of the Anti-myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-week Treatment Update","volume":"92","author":"Wagner","year":"2019","journal-title":"Neurol. Conf. 71st Annu. Meet. Am. Acad. Neurol. AAN."},{"key":"B91","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10974-019-09535-9","article-title":"What Is the Level of Dystrophin Expression Required for Effective Therapy of Duchenne Muscular Dystrophy?","volume":"40","author":"Wells","year":"2019","journal-title":"J. Muscle Res. Cel Motil"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/anie.201912392","article-title":"Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid","volume":"59","author":"Wilkinson","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.735912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T07:04:29Z","timestamp":1635750269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.735912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":92,"alternative-id":["10.3389\/fphar.2021.735912"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.735912","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"735912"}}